From demand for cheaper products to FDA, CBD firms faces tough road

From demand for cheaper products to regulatory challenges, CBD brands face a difficult road going into 2023.

Related Keywords

United States ,American ,Douglas Stearn ,Kristi Muldoon Jacobs ,Bethany Gomez ,Exchange Commission ,Charlotte Web Holdings Inc ,Cv Sciences Inc ,Cv Sciences ,Brightfield Group ,Web Holdings ,Natural Products Insider ,